Core Insights - BeyondSpring Pharmaceuticals (BYSI) experienced a stock price increase of 2.24% on August 13, reaching $2.055 per share, with a total market capitalization of $82.86 million [1] - As of June 30, 2024, the company reported total revenue of $1 million, reflecting a year-over-year growth of 14.29%, while the net profit attributable to shareholders was -$7.262 million, showing a 42.91% increase in losses compared to the previous year [1] Company Overview - BeyondSpring is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, including advanced tumor immunotherapy [2] - The company was founded in 2013 and is headquartered in the United States, with a mission to transform cancer treatment through unique academic and business capabilities [2] - The primary project, Plinabulin, is derived from natural compounds and has therapeutic potential for various cancers due to its biochemical activities [2] - BeyondSpring employs an innovative and highly scalable business model that integrates resources from both the U.S. and China to efficiently and cost-effectively achieve drug approval and development [2] - Target research areas include non-small cell lung cancer, prevention of neutropenia, and the combination of Plinabulin with PD-1 monoclonal antibodies [2]

[Corporate and Clinical Highlights](index=1&type=section&id=Corporate%20and%20Clinical%20Highlights) BeyondSpring reported significant clinical progress for Plinabulin in NSCLC and SEED Therapeutics achieved FDA IND clearance for ST-01156 [CEO's Statement](index=1&type=section&id=CEO%27s%20Statement) CEO Dr. Lan Huang emphasized Plinabulin's immune-modulating potential and SEED Therapeutics' ST-01156 FDA IND clearance - Plinabulin is positioned as a first-in-class agent that harnesses the body's immune system by maturing dendritic cells, bridging innate and adaptive immunity[3](index=3&type=chunk) - The combination of plinabulin and docetaxel has shown durable survival benefits and reduced chemotherapy-induced neutropenia in a global Phase 3 trial[3](index=3&type=chunk) - SEED Therapeutics' oral RBM39 molecular glue degrader, ST-01156, received FDA clearance to enter clinical trials for aggressive cancers like Ewing Sarcoma and KRAS-driven tumors[3](index=3&type=chunk) [Key Milestones](index=1&type=section&id=Key%20Milestones) Key milestones include Plinabulin's ASCO 2025 presentation, 'Med' publication, SEED Therapeutics' ST-01156 FDA IND clearance, and new leadership - ASCO 2025 presentation highlighted Plinabulin's ability to drive immune re-sensitization in NSCLC patients who have progressed on PD-1/L1 therapies[5](index=5&type=chunk) - A publication in 'Med' (Cell Press) detailed Plinabulin's rapid activation of dendritic cells in patients across eight cancer types who had failed prior immunotherapy[5](index=5&type=chunk) - SEED Therapeutics' lead asset, RBM39 degrader ST-01156, received FDA IND clearance and is advancing toward Phase 1 trials[5](index=5&type=chunk) - Dr. Bill Desmarais was appointed as the new CFO and CBO of SEED Therapeutics to accelerate development[5](index=5&type=chunk) [Plinabulin Clinical Updates](index=1&type=section&id=Plinabulin%20Clinical%20Updates) Plinabulin's Phase 2 NSCLC study showed encouraging efficacy, and a publication with MD Anderson confirmed its dendritic cell maturation mechanism Plinabulin Phase 2 NSCLC Study Efficacy Data (ASCO 2025) | Metric | Result | | :--- | :--- | | Median Progression-Free Survival (PFS) | 6.8 months | | Confirmed Objective Response Rate (ORR) | 18.2% | | Duration of Response (DOR) | 7.2 months | | Disease Control Rate (DCR) | 77% | | Overall Survival (OS) at 15 months | 78% | - A study with MD Anderson showed Plinabulin, combined with radiation and a checkpoint inhibitor, rapidly induces dendritic cell maturation in patients who failed prior immunotherapy[6](index=6&type=chunk) - In the MD Anderson study across eight cancer types, the combination therapy achieved an Objective Response Rate (ORR) of **23%** and a Disease Control Rate (DCR) of **54%**[6](index=6&type=chunk) [SEED Therapeutics Updates](index=1&type=section&id=SEED%20Therapeutics%20Updates) SEED Therapeutics achieved FDA IND clearance for ST-01156, showing complete tumor regression in preclinical models, and appointed new leadership - The FDA cleared the IND application for ST-01156, a brain-penetrant, novel orally administered molecular glue degrader targeting RBM39[6](index=6&type=chunk)[7](index=7&type=chunk) - Preclinical data presented at AACR 2025 showed ST-01156 demonstrated complete tumor regression in Ewing Sarcoma models[9](index=9&type=chunk) - Dr. Bill Desmarais, Ph.D., MBA, joined SEED Therapeutics as CFO and Chief Business Officer, bringing over two decades of biopharma leadership experience[9](index=9&type=chunk) [Financial Performance](index=2&type=section&id=Financial%20Performance) BeyondSpring reported a reduced Q2 2025 net loss from continuing operations, improved cash, and reclassified SEED Therapeutics as discontinued operations [Q2 2025 Financial Results Summary](index=2&type=section&id=Q2%202025%20Financial%20Results%20Summary) Q2 2025 saw increased R&D, reduced G&A, a lower net loss, and a strengthened cash position for continuing operations Q2 Financial Highlights (Continuing Operations) | Metric | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | R&D Expenses | $1.0 million | $0.8 million | | G&A Expenses | $0.9 million | $1.8 million | | Net Loss | $1.9 million | $2.7 million | Cash Position | Metric | June 30, 2025 | Dec 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $9.5 million | $2.9 million | [Year-to-Date 2025 Financial Results Summary](index=2&type=section&id=Year-to-Date%202025%20Financial%20Results%20Summary) Year-to-date 2025 showed a slightly improved net loss from continuing operations and a total net income including discontinued operations Six-Month Financial Highlights (Continuing Operations) | Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | R&D Expenses | $1.9 million | $1.6 million | | G&A Expenses | $2.7 million | $3.1 million | | Net Loss | $4.5 million | $4.7 million | - Net income from discontinued operations was **$1.0 million** for the first six months of 2025, compared to a net loss of **$2.6 million** for the same period in 2024[8](index=8&type=chunk) [Accounting for SEED Therapeutics](index=2&type=section&id=Accounting%20for%20SEED%20Therapeutics) BeyondSpring reclassified SEED Therapeutics' financial results as discontinued operations after agreements to reduce its ownership stake - SEED Therapeutics' financial results are now reported as discontinued operations under ASC 205-20[9](index=9&type=chunk) - BeyondSpring's ownership in SEED is set to be reduced from approximately **40%** to **14%** upon completion of future sale transactions[10](index=10&type=chunk) [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2025, BeyondSpring's balance sheet showed increased cash, stable assets and liabilities, and a widened shareholders' deficit Selected Balance Sheet Data (in thousands) | Balance Sheet Item | June 30, 2025 | Dec 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $9,544 | $2,922 | | Total assets | $31,043 | $34,315 | | Total liabilities | $48,588 | $48,600 | | Total shareholders' deficit | ($17,545) | ($14,285) | [Condensed Consolidated Statements of Comprehensive Income (Loss)](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Comprehensive%20Income%20%28Loss%29) Q2 2025 showed no revenue and a net loss from continuing operations, with year-to-date results including net income from discontinued operations Income Statement Summary (in thousands, except per share data) | Metric | Q2 2025 | Q2 2024 | Six Months 2025 | Six Months 2024 | | :--- | :--- | :--- | :--- | :--- | | Revenue | $0 | $0 | $0 | $0 | | Loss from operations | ($1,949) | ($2,641) | ($4,559) | ($4,696) | | Net loss from continuing ops | ($1,878) | ($2,651) | ($4,462) | ($4,731) | | Net income (loss) from discontinued ops | ($2,771) | ($1,438) | $983 | ($2,646) | | EPS (Continuing ops) | ($0.04) | ($0.07) | ($0.11) | ($0.12) | [Company Overview](index=3&type=section&id=Company%20Overview) BeyondSpring is a clinical-stage biopharmaceutical company developing first-in-class therapies, featuring Plinabulin and affiliate SEED Therapeutics [About BeyondSpring](index=3&type=section&id=About%20BeyondSpring) BeyondSpring is a clinical-stage biopharmaceutical company focused on developing Plinabulin, a late-stage anti-cancer agent for NSCLC - The company's lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in NSCLC[11](index=11&type=chunk) - Plinabulin's novel mechanism as a dendritic cell maturation agent offers a unique approach to resensitizing tumors resistant to checkpoint inhibitors[11](index=11&type=chunk) [About SEED Therapeutics](index=3&type=section&id=About%20SEED%20Therapeutics) SEED Therapeutics specializes in targeted protein degradation via its RITE3™ platform, developing a pipeline with strategic partners - SEED Therapeutics pioneers targeted protein degradation through its proprietary RITE3™ platform[12](index=12&type=chunk) - The company has strategic collaborations with major pharmaceutical companies Eli Lilly and Eisai[12](index=12&type=chunk) - SEED's lead RBM39 degrader program has received US FDA IND clearance[12](index=12&type=chunk) [Cautionary Note Regarding Forward-Looking Statements](index=3&type=section&id=Cautionary%20Note%20Regarding%20Forward-Looking%20Statements) This section warns that forward-looking statements are subject to significant risks and uncertainties, which could cause actual results to differ - The press release contains forward-looking statements that are not historical facts and are based on current knowledge, beliefs, and expectations[13](index=13&type=chunk) - Actual results could differ materially due to risks such as difficulties in raising capital, unexpected clinical trial results, regulatory delays, and market competition[13](index=13&type=chunk)

Core Insights - BeyondSpring Inc. reported Q2 2025 financial results and highlighted significant clinical and corporate milestones, focusing on its lead asset, Plinabulin, which is positioned to redefine cancer treatment by leveraging the immune system [1][2]. Clinical Developments - Plinabulin is a first-in-class agent that matures dendritic cells, potentially offering new hope to 60% of non-small cell lung cancer (NSCLC) patients whose disease progresses after checkpoint inhibitor therapy [2]. - In the global Phase 3 trial (Dublin-3), the combination of Plinabulin and docetaxel showed durable survival benefits and reduced chemotherapy-induced neutropenia compared to standard docetaxel alone [2]. - New data from a Phase 2 study indicated that the combination of pembrolizumab, Plinabulin, and docetaxel in metastatic NSCLC patients demonstrated a median progression-free survival (PFS) of 6.8 months and an overall survival (OS) of 78% at 15 months [5]. - A collaboration with MD Anderson highlighted Plinabulin's rapid dendritic cell activation across eight cancer types, reporting an objective response rate (ORR) of 23% and a disease control rate (DCR) of 54% [5]. Corporate Milestones - SEED Therapeutics, in which BeyondSpring is a founding shareholder, received FDA clearance for its RBM39 molecular glue degrader, ST-01156, targeting aggressive cancers [2][4]. - Dr. Bill Desmarais joined SEED Therapeutics as CFO and CBO, bringing over 20 years of biotech leadership experience [6]. Financial Performance - For the six months ended June 2025, BeyondSpring reported a net income of $1 million, an improvement from a net loss of $2.6 million in the same period of 2024 [7]. - Research and development (R&D) expenses increased to $1.9 million for the six months ended June 2025, compared to $1.6 million in the prior year, primarily due to higher professional service fees [9]. - General and administrative (G&A) expenses decreased to $2.7 million for the six months ended June 2025, down from $3.1 million in the same period of 2024 [9]. Financial Position - As of June 30, 2025, cash and cash equivalents stood at $9.5 million, a significant increase from $2.9 million as of December 2024 [9]. - Current assets totaled $15.7 million, down from $25.3 million as of December 2024, reflecting the impact of discontinued operations [9].

Core Insights - BeyondSpring Pharmaceuticals (BYSI) opened with a 2.5% increase, reaching $2.05 per share, with a total market capitalization of $82.66 million as of 21:30 [1] - For the fiscal year ending June 30, 2024, the company reported total revenue of $1.00 million, reflecting a year-over-year growth of 14.29%, while the net profit attributable to shareholders was -$7.26 million, showing a 42.91% increase in losses compared to the previous year [1] Company Overview - BeyondSpring is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, including advanced tumor immunotherapy [1] - The company was founded in 2013 and is headquartered in the United States, with a mission to transform cancer treatment through its academic and business capabilities [1] - The primary project, Plinabulin, is derived from natural compounds and has therapeutic potential for various cancers, targeting areas such as non-small cell lung cancer and the prevention of neutropenia [1] Business Model and Strategy - BeyondSpring employs a novel, highly scalable business model that integrates resources from both the U.S. and China to efficiently and cost-effectively achieve drug approval and development [1] - The company's research focus includes Plinabulin in combination with PD-1 monoclonal antibodies [1]

Core Insights - BeyondSpring Pharmaceuticals (BYSI) experienced a stock price increase of 3.19% on August 8, reaching $2.105 per share, with a total market capitalization of $84.8785 million [1] - As of June 30, 2024, the company reported total revenue of $1 million, reflecting a year-over-year growth of 14.29%, while the net profit attributable to shareholders was -$7.262 million, showing a 42.91% increase in losses compared to the previous year [1] - The company is focused on developing novel cancer therapies, particularly advanced tumor immunotherapy, and aims to transform cancer treatment through its unique academic and business capabilities [1] Financial Performance - Total revenue for the fiscal year ending June 30, 2024, is projected at $1 million, marking a 14.29% increase year-over-year [1] - The net profit attributable to shareholders is reported at -$7.262 million, which is a 42.91% increase in losses compared to the previous year [1] Company Overview - BeyondSpring Pharmaceuticals is a clinical-stage biopharmaceutical company established in 2013, headquartered in the United States [1] - The company specializes in the research and development of new cancer therapies, including treatments for non-small cell lung cancer and the prevention of neutropenia [1] - The main project, Plinabulin, is derived from natural compounds and has therapeutic potential for various cancers [1] - BeyondSpring employs a novel, highly scalable business model that integrates resources from the U.S. and China to efficiently and cost-effectively achieve drug approval and development [1]

Group 1 - The stock price of BeyondSpring Inc. (BYSI) increased by 5.07% on August 6, reaching $2.154 per share, with a total market capitalization of $86.8373 million [1] - As of June 30, 2024, BeyondSpring reported total revenue of $1.0 million, reflecting a year-over-year growth of 14.29%, while the net profit attributable to shareholders was -$7.262 million, showing a year-over-year increase of 42.91% [1] Group 2 - BeyondSpring is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, including advanced tumor immunotherapy [2] - The company was founded in 2013 and is headquartered in the United States, with a mission to transform cancer treatment through its academic and business capabilities [2] - The main project, Plinabulin, is derived from natural compounds and has therapeutic potential for various cancers, with a novel, scalable business model aimed at efficient and low-cost drug approval and development [2] - Target research areas include non-small cell lung cancer, prevention of neutropenia, and Plinabulin combined with PD-1 monoclonal antibodies [2]

Core Insights - BeyondSpring Pharmaceuticals (BYSI) experienced a stock price increase of 3.41% on August 6, reaching $2.12 per share, with a total market capitalization of $85.47 million [1] - As of June 30, 2024, the company reported total revenue of $1.00 million, reflecting a year-over-year growth of 14.29%, while the net profit attributable to shareholders was -$7.26 million, showing a 42.91% increase in losses compared to the previous year [1] - The company is set to disclose its fiscal year 2024 annual report on May 5, with the actual release date subject to company announcements [1] Company Overview - BeyondSpring Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, including advanced tumor immunotherapy [1] - Founded in 2013 and headquartered in the United States, the company aims to leverage its academic and business expertise in cancer treatment to transform the current landscape of cancer therapy [1] - The primary project, Plinabulin, is derived from natural compounds and has therapeutic potential for various cancers due to its biochemical activities [1] Business Model and Research Focus - The company employs an innovative and highly scalable business model that integrates resources from both the U.S. and China to efficiently and cost-effectively achieve drug approval and development [1] - Key research areas include non-small cell lung cancer, prevention of neutropenia, and the combination of Plinabulin with PD-1 monoclonal antibodies [1]

Core Insights - BeyondSpring Pharmaceuticals (BYSI) opened with a 4.35% increase on August 5, trading at $2.16 per share, with a total market capitalization of $87.083 million [1] - As of June 30, 2024, the company reported total revenue of $1.0 million, reflecting a year-over-year growth of 14.29%, while the net profit attributable to shareholders was -$7.262 million, showing a 42.91% increase in losses compared to the previous year [1] Company Overview - BeyondSpring is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, including advanced tumor immunotherapy [2] - The company was founded in 2013 and is headquartered in the United States, with a mission to transform cancer treatment through unique academic and business capabilities [2] - The primary project, Plinabulin, is derived from natural compounds and has therapeutic potential for various cancers, targeting areas such as non-small cell lung cancer and the prevention of neutropenia [2] - BeyondSpring employs a novel, highly scalable business model that integrates resources from both the U.S. and China to efficiently and cost-effectively achieve drug approval and development [2]

Group 1 - The stock price of BeyondSpring Inc. (BYSI) increased by 5.8% on August 4, reaching $2.19 per share, with a total market capitalization of $88.29 million [1] - As of June 30, 2024, BeyondSpring reported total revenue of $1.00 million, representing a year-over-year growth of 14.29%, while the net profit attributable to the parent company was -$7.26 million, showing a year-over-year increase of 42.91% [1] - BeyondSpring is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, including advanced tumor immunotherapy [1] Group 2 - The company was founded in 2013 and is headquartered in the United States, with a mission to transform cancer treatment through its academic and business capabilities [1] - BeyondSpring's main project, Plinabulin, is derived from natural compounds and has therapeutic potential for various cancers due to its biochemical activities [1] - The company employs a novel, highly scalable business model that integrates resources from the U.S. and China to efficiently and cost-effectively achieve drug approval and development [1]

Core Insights - BeyondSpring Pharmaceuticals (BYSI) experienced a stock price increase of 3.38% on August 4, reaching $2.14 per share, with a total market capitalization of approximately $86.28 million [1] - As of June 30, 2024, the company reported total revenue of $1.00 million, reflecting a year-over-year growth of 14.29%, while the net loss attributable to shareholders was $7.26 million, which represents a 42.91% increase compared to the previous year [1] Company Overview - BeyondSpring Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, including advanced tumor immunotherapy [2] - The company was founded in 2013 and is headquartered in the United States, with a mission to transform cancer treatment through its academic and business capabilities [2] - The primary project, Plinabulin, is derived from natural compounds and has therapeutic potential for various cancers due to its biochemical activities [2] - BeyondSpring employs a novel, highly scalable business model that integrates resources from both the U.S. and China to efficiently and cost-effectively achieve drug approval and development [2] - Target research areas include non-small cell lung cancer, prevention of neutropenia, and Plinabulin combined with PD-1 monoclonal antibodies [2]